Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma

Bibliography

• ISHIZAKA K, ISHIZAKA T: Physicochemical properties of reaginic antibody. 1. Association of reaginic activity with an immunoglobulin other than yA- or 7G-globulin. Allergy (1966) 37:169–185.
   Google Scholar
• JOHANSSON SG, BENNICH H: Immunological studies of an atypical (myeloma) immunoglobulin.Immunology (1967) 13:381–394.
   PubMed Web of Science ®Google Scholar
• POLLART SM, CHAPMAN MD, FIOCCO GP, ROSE G,PLATTS-MILLS TA: Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. Allergy Clin. Immunol (1989) 83:875–882.
   Google Scholar
• BURROWS B, MARTINEZ FD, HALONEN M, BARBEE RA, CLINE MG: Association of asthma with serum IgE levels and skin-test reactivity to allergens.N Engl. J. Med. (1989) 320:271–277.
   PubMed Web of Science ®Google Scholar
• SEARS MR, BURROWS B,FLANNERY EM, HERBISON GP, HEWITT CJ, HOLDAWAY MD: Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children.N Engl. J. Med. (1991) 325:1067–1071.
   PubMed Web of Science ®Google Scholar
• PEAT JK, TOELLE BG, DERMAND J, VAN DEN BR, BRITTON WJ, WOOLCOCK AJ: Serum IgE levels, atopy, and asthma in young adults: results from a longitudinal cohort study. Allergy (1996) 51:804–810.
   PubMed Web of Science ®Google Scholar
• GREEN JM: The B7/CD28/CTLA4 T-cell activation pathway. Implications for inflammatory lung disease. Am. I Respir. Cell MM. Biol. (2000) 22:261–264.
   PubMedGoogle Scholar
• KAPLAN MH, SCHINDLER U, SMILEY ST, GRUSBY MJ: Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity (1996) 4:313–319.
   PubMed Web of Science ®Google Scholar
• HERSHEY GK, FRIEDRICH ME ESSWEIN LA, THOMAS ML,CHATILA TA: The association of atopy with a gain-of-function mutation in the a-subunit of the IL-4 receptor.N. Engl. J. Med. (1997) 337:1720–1725.
   PubMed Web of Science ®Google Scholar
• CHANG TW: The pharmacological basis of anti-IgE therapy. Nature Biotechnol (2000) 18:157–162.
   PubMed Web of Science ®Google Scholar
• RAJAKULASINGAM K, DURHAM SR, O'BRIEN F et al.: Enhanced expression of high-affinity IgE receptor (FcERI) a chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages,eosinophils, and dendritic cells.J. Allergy Clin. Immunol (1997) 100:78–86.
   Google Scholar
• BACHARIER LB, GEHA RS: Regulation of IgE synthesis: the molecular basis and implications for clinical modulation. Allergy Asthma Proc. (1999) 20:1–8.
   PubMedGoogle Scholar
• VERCELLI D, JABARA HH, ARAI K, GEHA RS: Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens. I Exp. Med. (1989) 169:1295–1307.
   PubMed Web of Science ®Google Scholar
• HELM BA, SPIVEY AC, PADLAN EA: Peptide blocking of IgE/receptor interaction: possibilities and pitfalls. Allergy (1997) 52:1155–1169.
   PubMedGoogle Scholar
• JARDIEU P: Anti-IgE therapy. Carr. Opin. Immunol (1995) 7:779–782.
   PubMedGoogle Scholar
• KITANI S, KRAFT D, FISCHLER C, MERGENHAGEN SE, SIRAGANIAN RP: Inhibition of allergic reactions with monoclonal antibody to the high affinity IgE receptor. Immunol (1988) 140:2585–2588.
   Google Scholar
• HABA S, NISONOFF A: Inhibition of IgEsynthesis by anti-IgE: role in long-terminhibition of IgE synthesis by neonatallyzadministered soluble IgE. Proc. Natl. Acad. Sci. USA (1990) 87:3363–3367.
   PubMedGoogle Scholar
• VAN NEERVEN RJ, VAN ROOMEN CP, THOMAS WR, DE BOER M, KNOL EF, DAVIS FM: Humanized anti-IgE mAb Hu-901 prevents the activation of allergen-specific T cells. Int. Arch. Allergy Immunol. (2001) 124:400–402.
   PubMedGoogle Scholar
• PRESTA LG, LAHR SJ, SHIELDS RL et al.: Humanization of an antibody directed against IgE. Immunol (1993) 151:2623–2632.
   Web of Science ®Google Scholar
• CORNE J, DJUKANOVIC R,THOMAS L et al.: The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.j. Clin. Invest. (1997) 99:879–887.
   Google Scholar
• YAMAGUCHI M, LANTZ CS,OETTGEN HC et al.: IgE enhances mouse mast cell Fc(E)RI expression M vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J. Exp. Med. (1997) 185:663–672.
   Google Scholar
• MACGLASHAN D JR, XIA HZ, SCHWARTZ LB, GONG J:IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcERI in human basophils. Leukoc. Biol. (2001) 70:207–218.
   PubMedGoogle Scholar
• MACGLASHAN DW, BOCHNER BS, ADELMAN DC et al.: Down-regulation of Fc(E)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. I Immunol (1997) 158:1438–1445.
   PubMed Web of Science ®Google Scholar
• MACGLASHAN D,LICHTENSTEIN LM,MCKENZIE-WHITE J et al.: Upregulation of FcERI on human basophils by IgE antibody is mediated by interaction of IgE with FcERI. I Allergy Clin. Immunol. (1999) 104:492–498.
   Google Scholar
• KOPP MV, BRAUBURGER J,RIEDINGER F et al: The effect of anti-IgE treatment on in vitro leukotriene release inchildren with seasonal allergic rhinitis.I Allergy Clin. Immunol (2002) 110:728–735.
   PubMed Web of Science ®Google Scholar
• DJUKANOVIC R, WILSON SJ, KRAFT M et al.: Effect of treatment with anti-IgE antibody (omalizumab) on airway inflammation in mild atopic asthma. Ant. Respir Grit. Care Med. (2003) 167(Suppl.) A703.
   Google Scholar
• BOULET LP, CHAPMAN KR, COTE J et al.: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response [see comments]. Am. I Respir. Grit. Care Med. (1997) 155:1835–1840.
   PubMed Web of Science ®Google Scholar
• FAHY JV, FLEMING HE, WONG HH et al.: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects [see comments]. Am. J. Respir. Crit. Care Med. (1997) 155:1828–1834.
   PubMed Web of Science ®Google Scholar
• MILGROM H, FICK RB, SU JQ et al.: Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.N. Engl. J. Med. (1999) 341:1966–1973.
   Google Scholar
• SOLER M, MATZ J, TOWNLEY R et al.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. (2001) 18:254–261.
   PubMed Web of Science ®Google Scholar
• BUSSE W, CORREN J, LANIER BQ et al:Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.I Allergy Clin. Immunol (2001) 108:184–190.
   PubMed Web of Science ®Google Scholar
• FINN A, GROSS G, VAN BAVEL J et al.:Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. I Allergy Clin. Immunol (2003) 111:278–284.
   Google Scholar
• BUHL R, HANF G, SOLER M et al.: The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma.Eur. Respir (2002) 20:1088–1094.
   PubMed Web of Science ®Google Scholar
• BUSSE W, CORREN J, LANIER BQ et al: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.I Allergy Clin. Immunol (2001) 108:184–190.
   PubMed Web of Science ®Google Scholar
• SOLER M, MATZ J, TOWNLEY R et al.:The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. (2001) 18:254–261.
   PubMed Web of Science ®Google Scholar
• HOLGATE ST, CHUCHALIN A, HERBERT D, LOTVALL J, CHUNG KF, BOUSQUET J: Omalizumab (Xolair, rhumab-E25), a novel therapy for severe allergic asthma. Am. I Respir. Grit. Care Med. (2001) 163(Suppl.):A812.
   Google Scholar
• HOLGATE ST, BOUSQUET J, WENZEL S, FOX H, LIU J,CASTELLSAGUE J:Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Carr. Med. Res. Opin. (2001) 17:233–240.
   PubMed Web of Science ®Google Scholar
• MILGROM H, BERGER W, NAYAK A et al.: Treatment of childhood asthma with anti-immunoglobulin e antibody (omalizumab). Pediatrics (2001) 108:E36.
   PubMed Web of Science ®Google Scholar
• CORREN J, CASALE T, DENIZ Y, ASHBY M: Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. I Allergy Clin. Immunol (2003) 111:87–90.
   PubMed Web of Science ®Google Scholar
• CHUNG KF, KUNKEL G, RAMOS S, AYRE G, FOX H, BLOGG M: Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly-controlled moderate-to-severe allergic asthma. Eur. Respir. 1 (2003)22 (Suppl. 45):5203
   Google Scholar
• LEMANSKE RF Jr, NAYAK A, MCALARY M, EVERHARD F, FOWLER-TAYLOR A, GUPTA N: Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics (2002) 110:E55.
   Google Scholar
• ADELROTH E, RAK S, HAAHTELA T et al.: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. I Allergy Clin. Immunol (2000) 106:253–259.
   PubMed Web of Science ®Google Scholar
• CASALE TB, BERNSTEIN IL, BUSSE WW et al.: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol (1997) 100:110–121.
   PubMed Web of Science ®Google Scholar
• CASALE TB, CONDEMI J, LAFORCE Cet al: Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA (2001) 286:2956–2967.
   PubMed Web of Science ®Google Scholar
• VIGNOLA M, BOUSQUET J,MASPERO J, FOX H, HEDGECOCK S, BLOGG M: Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent. omalizumab. Eur. Respir (2003) 22\(Suppl. 45):5203.
   Google Scholar
• KUEHR J, BRAUBURGERJ, ZIELEN Set al.: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. I Allergy Clin. Immunol (2002) 109:274–280.
   Google Scholar
• LEUNG DY, SAMPSON HA,YUNGINGER JW et al.: Effect of anti-IgEtherapy in patients with peanut allergy.N Engl. J. Med. (2003) 348:986–993.
   PubMed Web of Science ®Google Scholar